Tempus AI (NASDAQ:TEM) Shares Gap Down – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares gapped down before the market opened on Thursday . The stock had previously closed at $85.71, but opened at $79.99. Tempus AI shares last traded at $74.08, with a volume of 7,986,420 shares.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TEM. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Finally, TD Cowen reiterated a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Down 13.6 %

The stock has a fifty day moving average of $49.05 and a 200-day moving average of $51.26. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Activity

In related news, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the transaction, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at approximately $3,434,220. This represents a 19.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the transaction, the chief executive officer now owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,401,779 shares of company stock worth $115,707,361 over the last ninety days.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. bought a new stake in Tempus AI in the 3rd quarter valued at $30,000. Operose Advisors LLC acquired a new stake in Tempus AI in the 4th quarter worth about $25,000. Farther Finance Advisors LLC bought a new stake in Tempus AI in the 4th quarter valued at about $34,000. Prestige Wealth Management Group LLC grew its position in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new position in shares of Tempus AI during the fourth quarter worth approximately $49,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.